Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2024, with the report dated February 1, 2024. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of Jan 31, 2024): 4,313,761,992 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 197,068,169 Ordinary Shares.
- Total Voting Rights: 4,116,693,823.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance. The document reports the static capital position as of January 31, 2024, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under FCA rules.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,116,693,823) to determine if notification of interest changes is required under FCA rules.
- Confirm the number of shares held in Treasury (197,068,169) when calculating the denominator for ownership percentage.
- Note that this filing contains no financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.